60.81USD-3.66%Mkt Cap: 410.92M USDP/E: —Last update: 2026-05-26
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational onc…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap410.92M USD
Enterprise Value282.63M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-13.72M USD
Revenue/Share—
Last Price60.81 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees22
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS61023L1089
Valuation
P/E (Trailing)—
P/E (Forward)-19.48
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B3.04
EPS (TTM)-1.93
EPS (Forward)-3.22
52W Range
28.4042% of range105.00
52W High105.00 USD
52W Low28.40 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-9.95%
ROA-9.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.20M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-1.31%
Net Debt-137.26M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio56.05
Quick Ratio55.94
Book Value/Sh20.59 USD
Cash/Share20.52 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateAug 13, 2024
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)112.62 USD
Target Range100.00 USD – 130.00 USD
# Analysts13
Ownership
Shares Out.6.70M
Float4.13M
Insiders23.23%
Institutions93.27%
Short Interest
Short Ratio9.9d
Short % Float36.53%
Short % Out.24.94%
Shares Short1.67M
Short (prev mo.)1.68M
Technical
SMA 5057.06 (+6.6%)
SMA 20063.96 (-4.9%)
Beta1.50
S&P 52W Chg28.31%
Avg Vol (30d)184.09K
Avg Vol (10d)243.22K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—